Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.

ABSTRACT:

Background

Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding of ARCM in the trastuzumab era.

Methods

This retrospective observational cohort study included 2959 patients with BC treated with anthracyclines at three regional cancer centers in Niigata City between 1990 and 2020. Seventy-five patients (2.5%) developed ARCM and were categorized into two groups: pre- 2007 (early phase) and post-2007 (late phase), corresponding to before and during the trastuzumab era in Japan.

Results

ARCM incidence peaked at 6% in the 1990s, then decreased and stabilized at 2% until the 2010s. Survivo

SUBMITTER: Watanabe M 

PROVIDER: S-EPMC11489246 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature